Literature DB >> 3149737

Serum protein binding of AL01576, a new aldose reductase inhibitor.

P J McNamara1, R A Blouin, R K Brazzell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3149737     DOI： 10.1023/a:1015939023465

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


× No keyword cloud information.
  4 in total

1.  Dose-dependent pharmacokinetics of the aldose reductase inhibitor imirestat in man.

Authors:  R K Brazzell; P R Mayer; R Dobbs; P J McNamara; R L Teng; J T Slattery
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

2.  Pharmacokinetics of the aldose reductase inhibitor imirestat following topical ocular administration.

Authors:  R K Brazzell; C B Wooldridge; R B Hackett; B A McCue
Journal:  Pharm Res       Date:  1990-02       Impact factor: 4.200

3.  Comparison of the pharmacokinetics and pharmacodynamics of the aldose reductase inhibitors, AL03152 (RS), AL03802 (R), and AL03803 (S).

Authors:  Y H Park; P R Mayer; R Barker; M DuPriest; B W Griffin; G W Williams; B M York; J T Slattery
Journal:  Pharm Res       Date:  1993-04       Impact factor: 4.200

4.  The protein binding of phenytoin, propranolol, diazepam, and AL01576 (an aldose reductase inhibitor) in human and rat diabetic serum.

Authors:  P J McNamara; R A Blouin; R K Brazzell
Journal:  Pharm Res       Date:  1988-05       Impact factor: 4.200
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.